OTC:AXIM
AXIM BIOTECHNOLOGIES, INC.
A biotech developer with heavy R&D burn and negative net income seeking to transition from a high-debt, loss-making stage to commercial viability.
Key Metrics
Investment Thesis
Bull Case
An investor might buy if they believe in the unproven potential of the company's biotech pipeline to eventually generate blockbuster revenues that could clear its debt burden.
Bear Case
The stock is risky because the company is burning cash at a rate of over $1M annually with no revenue, leaving it unable to fund operations without further dilution or restructuring.
About AXIM BIOTECHNOLOGIES, INC.
AXIM Biotechnologies is a biotechnology firm focused on developing novel therapeutics, though recent filings indicate minimal current revenue generation. The company operates with significant cash outflows driven by research and development expenses and substantial debt obligations. It targets markets requiring innovative medical solutions but faces challenges in commercializing its pipeline without consistent income streams.
Analysis
Management Discussion
Management has reported a significant deterioration in performance, shifting from a positive net income of $6.2M to a substantial loss of $8.1M while failing to generate any revenue over the last two years. The balance sheet is under severe strain with total liabilities of $11.8M against only $4.1M in assets and a negative shareholders' equity position.
Industry Overview
The biotechnology industry is characterized by high upfront costs for R&D and long development cycles before any product reaches market, often resulting in significant losses during the early growth phase.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 |
|---|---|---|
| Revenue | $8.9K | $39.5K |
| Cost of Revenue | $0 | $0 |
| Gross Profit | $8.9K | $39.5K |
| Operating Expenses | $4.7M | $2.8M |
| Operating Income | $-4.7M | $-2.8M |
| R&D | $153.7K | $125.5K |
| G&A | $4.1M | $2.2M |
| Stock-Based Comp | $1.1M | $197.7K |
| D&A | $426.1K | $427.0K |
| Depreciation | $31.7K | $32.6K |
| Amortization | $394.4K | $394.4K |
| Other OpEx | $311.6K | $427.0K |
| Non-Operating Income | $-1.6M | $-5.3M |
| Interest Income | — | $0 |
| Pre-Tax Income | $-6.2M | $-8.1M |
| Income Tax | $0 | $0 |
| Continuing Ops | $-6.2M | $0 |
| Discontinued Ops | $0 | $-8.1M |
| Net Income | $6.2M | $-8.1M |
| Minority Interest | $0 | $0 |
| Net to Common | $6.2M | $-8.1M |
| Metric | 2022 | 2023 |
|---|---|---|
| Current Assets | $104.0K | $156.5K |
| Cash & Equivalents | $47.3K | — |
| Other Current Assets | $56.7K | — |
| Long-Term Assets | $4.1M | $4.0M |
| PP&E (Net) | $93.8K | $134.1K |
| Operating Leases | $19.8K | $227.0K |
| Other LT Assets | $4.0M | $3.6M |
| Total Assets | $4.2M | $4.1M |
| Current Liabilities | $3.4M | $6.0M |
| Other Current Liab | $3.4M | — |
| Long-Term Liabilities | $5.6M | $5.8M |
| Total Liabilities | $9.0M | $11.8M |
| Shareholders' Equity | $-4.8M | $-7.7M |
| Paid-In Capital | $59.2M | $64.5M |
| Retained Earnings | $-64.1M | $-72.2M |
| Total L&E | $4.2M | $4.1M |
| Metric | 2022 | 2023 |
|---|---|---|
| Net Income (CFO) | $6.2M | $-8.1M |
| Non-Cash Adjustments | $-9.4M | $6.0M |
| Working Capital Changes | $1.1M | $1.0M |
| Cash from Operations | $-2.0M | $-1.0M |
| Capital Expenditures | $8.7K | $0 |
| Cash from Investing | $-8.7K | $0 |
| Cash from Financing | $1.6M | $1.1M |
| FX Effect | $0 | $0 |
| Net Change in Cash | $-405.7K | $109.2K |
| Beginning Cash | $453.0K | $47.3K |
| Ending Cash | $47.3K | $156.5K |
Frequently Asked Questions
How does AXIM BIOTECHNOLOGIES, INC. make money?
The company's financials suggest a primary segment dedicated to early-stage research and development, evidenced by specific R&D spend and general administrative costs, while current operations show negligible revenue and no cost of goods sold.
What are the main risks for AXIM?
The company faces extreme liquidity risk due to a net loss of $8.1M against minimal cash reserves, high leverage with total liabilities exceeding assets, and an inability to generate operating profit.
What is AXIM's competitive advantage?
Potential advantages include access to proprietary biotechnology platforms for drug discovery and the ability to partner with larger pharmaceutical entities to offset development costs.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.